MedTrace Logo

Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

NCT07792681 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 2079

Last updated 2026-08-28

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines

Conditions

  • Migraine, With or Without Aura

Interventions

DRUG

BR005-036C

Dose 1, Oral tablet

DRUG

BR005-036C

Dose 2, Oral tablet

DRUG

Placebo

Placebo tablet to match BR005-036C dose, Oral

Sponsors & Collaborators

  • Brise Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2028-06-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792681 on ClinicalTrials.gov